Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Oct;11(5):1924-1942.
doi: 10.1007/s13346-020-00885-3. Epub 2021 Jan 15.

Towards the use of localised delivery strategies to counteract cancer therapy-induced cardiotoxicities

David S Monahan  1   2   3 , Talal Almas  4 , Robert Wyile  1 , Faisal H Cheema  5   6 , Garry P Duffy  1   2   7   8   9 , Aamir Hameed  10   11
Affiliations
Review

Towards the use of localised delivery strategies to counteract cancer therapy-induced cardiotoxicities

David S Monahan et al. Drug Deliv Transl Res. 2021 Oct.

Abstract

Cancer therapies have significantly improved cancer survival; however, these therapies can often result in undesired side effects to off target organs. Cardiac disease ranging from mild hypertension to heart failure can occur as a result of cancer therapies. This can warrant the discontinuation of cancer treatment in patients which can be detrimental, especially when the treatment is effective. There is an urgent need to mitigate cardiac disease that occurs as a result of cancer therapy. Delivery strategies such as the use of nanoparticles, hydrogels, and medical devices can be used to localise the treatment to the tumour and prevent off target side effects. This review summarises the advancements in localised delivery of anti-cancer therapies to tumours. It also examines the localised delivery of cardioprotectants to the heart for patients with systemic disease such as leukaemia where localised tumour delivery might not be an option.

Keywords: Cancer therapy; Cardioprotectant; Cardiotoxicity; Immune checkpoint inhibitors; Localised drug delivery; Myocarditis.

PubMed Disclaimer

References

    1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin [Internet]. 2018;68(6):394–424. https://doi.org/10.3322/caac.21492 . - DOI
    1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin [Internet]. 2018;68(1):7–30. https://doi.org/10.3322/caac.21442 . - DOI
    1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2020;70(1):7–30. - DOI
    1. Herrmann J. Adverse cardiac effects of cancer therapies: cardiotoxicity and arrhythmia. Nat Rev Cardiol [Internet]. 2020; Available from: https://doi.org/10.1038/s41569-020-0348-1
    1. Zamorano JL, Lancellotti P, Rodriguez Muñoz D, Aboyans V, Asteggiano R, Galderisi M, et al. ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ES. Eur Heart J [Internet]. 2016;37(36):2768–801. https://doi.org/10.1093/eurheartj/ehw211 . - DOI

Publication types

LinkOut - more resources